INTERVIEW: Collaboration Key For China Regulatory Reforms, RDPAC Says (Part 1)
This article was originally published in PharmAsia News
Executive Summary
The days when foreign investments were welcomed with open arms in China seem to be gone, and a toughening environment is setting in. As the head of the top multinational research-based pharma association in the country, RDPAC managing director Joseph Cho is looking to local partnerships to help pursue regulatory reforms and expand new drug access in a rapidly changing market.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.